SCHEMBL19209469

SCHEMBL19209469

CCOC(=O)c1c(-c2ccccc2)nn(C)c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 6/20 0.57
SMN1; SMN2 Q16637 5/20 0.54
ALDH1A1 P00352 4/20 0.54
MAPT P10636 3/20 0.54
HPGD P15428 3/20 0.54
KDM4E B2RXH2 2/20 0.54
LMNA P02545 2/20 0.54
GAA P10253 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
PDE4D Q08499 1/20 0.53
TSHR P16473 4/20 0.51
TP53 P04637 1/20 0.51
KMT2A Q03164 2/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16061880 0.86 HTT (0.56) ADORA3SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL14747228 0.86 TSHR (0.57) ADORA3SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL12264906 0.85 TP53 (0.64) SMN1; SMN2ALDH1A1MAPTHPGDLMNA
SCHEMBL16877267 0.84 JAK2 (0.49) ADORA3SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL8062280 0.84 ADORA3 (0.53) ADORA3SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL6264973 0.83 PDE4D (0.73) ADORA3SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL9956863 0.82 KMT2A (0.67) SMN1; SMN2ALDH1A1HPGDKDM4ELMNA
SCHEMBL19209464 0.81 MAPK1 (0.60) ADORA3SMN1; SMN2ALDH1A1MAPTKDM4E
SCHEMBL19209495 0.80 TSHR (0.57) ADORA3SMN1; SMN2ALDH1A1MAPTHPGD
SCHEMBL14747500 0.80 ALDH1A1 (0.52) ADORA3SMN1; SMN2ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
EP-3411375-B1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2020-08-05 EP disclosed
EP-3411375-B1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2020-08-05 EP disclosed
US-10189844-B2 Pyrazole derivatives as phosphoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2019-01-29 US disclosed
US-10189844-B2 Pyrazole derivatives as phosphoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2019-01-29 US disclosed
EP-3411375-A1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2018-12-12 EP disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed
WO-2017134053-A1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2017-08-10 WO disclosed
WO-2017134053-A1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2017-08-10 WO disclosed
US-20170226109-A1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2017-08-10 US disclosed
US-20170226109-A1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2017-08-10 US disclosed
US-20170226109-A1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 ADORA3 4217/4885SMN1; SMN2 200/4885ALDH1A1 4193/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 ADORA3 3876/4885SMN1; SMN2 263/4885ALDH1A1 4421/4885
US-10189844-B2 Pyrazole derivatives as phosphoinositide 3-kinases inhibitors PI4KA, PI4KB, PI4K2B ADORA3 3475/4885SMN1; SMN2 3039/4885ALDH1A1 3454/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 ADORA3 4217/4885SMN1; SMN2 200/4885ALDH1A1 4193/4885
US-20170226109-A1 PYRAZOLE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS PI4KA, PI4KB, PI4K2B ADORA3 3475/4885SMN1; SMN2 3039/4885ALDH1A1 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.